Phase I Trial of Maintenance Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Post Allogeneic Bone Marrow Transplantation.

Trial Profile

Phase I Trial of Maintenance Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Post Allogeneic Bone Marrow Transplantation.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 08 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
    • 25 Jan 2016 Planned primary completion date changed from 1 Oct 2014 to 1 Oct 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top